Ameriprise
KTTA icon

Ameriprise’s Pasithea Therapeutics KTTA Stock Holding History

Ameriprise’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$961K Buy
1,864,485
+513,589
+38% +$353K ﹤0.01% 3419
2026
Q1 		$1M Sell
1,350,896
-579,232
-30% -$484K ﹤0.01% 3296
2025
Q4 		$2.49M Buy
+1,930,128
New +$1.7M ﹤0.01% 2876

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ameriprise's KTTA Position: Q2 2026 in Review

Ameriprise increased its Pasithea Therapeutics (KTTA) stake by 38% in Q2 2026, buying an estimated $353K and bringing the position to 1,864,485 shares worth $961K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

Ameriprise first reported a position in KTTA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.49M in Q4 2025. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Ameriprise held 1,864,485 shares of Pasithea Therapeutics worth $961K as of Q2 2026.
  • Ameriprise bought 513,589 Pasithea Therapeutics shares in Q2 2026, an estimated $353K.
  • Pasithea Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3419 holding.
  • Ameriprise first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Ameriprise's Pasithea Therapeutics position peaked at $2.49M in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.